Patients Without Standard Modifiable Cardiovascular Risk Factors (SMuRF-less) and Their Prognosis After a ST-segment-Elevation Myocardial Infarction (STEMI)

• Conditions: STEMI

• Registration Number: NCT05321667
• Lead Sponsor: Central Hospital, Nancy, France

Brief Summary

The purpose of this study is to asses the prognosis of STEMI patients without standard modifiable risk factors of cardiovascular disease (diabetes mellitus, hyperlipidemia, hypertension and cigarette smoking) compare to patients presenting at least one of these risk factors.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-03-26
• Status Verified: 2022-04
• Study Start: 2022-04-01
• Primary Completion: 2022-04-01
• Study First Submitted QC: 2022-04-04
• Last Update Submitted: 2022-04-04
• Study First Posted: 2022-04-11
• Last Update Posted: 2022-04-11
• Study Completion: 2022-08-31

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

STEMI patients who had a percutaneous coronary intervention (PCI) in our PCI center.

Exclusion Criteria

Pain duration exceeding 24h. Perioperative STEMI, including STEMI related to cardiac surgery.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
MACE (Major Adverse Cardiovascular Event)	3 years	Composite outcome including cardiovascular death or incidence of acute coronary syndrome, ischemic stroke or heart failure.

Secondary Outcome Measures

Name	Time	Method
All-cause mortality	3 years
Number of patients presenting heart failure during the follow-up	3 years	Number of patients hospitalized for acute heart failure during the follow-up, as well as patients presenting persistent symptoms of chronic heart failure after their STEMI (dyspnea NYHA \> 1) and/or long-terme need for diuretics.
Number of patients presenting cardiovascular death during the follow-up	3 years	Number of patients presenting death due to fatal myocardial infarction, fatal ischemic stroke, sudden death, severe heart failure and cardiogenic shock during the follow-up.
Number of patients presenting ischemic stroke during the follow-up	3 years	Number of patients presenting fatal or non fatal ischemic stroke during the follow-up

Trial Locations

Locations (1)

Institut du Coeur et des Vaisseaux Louis Mathieu; 🇫🇷 Vandœuvre-lès-Nancy, Meurthe-et-Moselle, France